Main Conference Day 2 - 13 November 2024 - CET (Central European Time, GMT+01:00)
Main Conference Day 2 - 13 November 2024 - CET (Central European Time, GMT+01:00)
- Jyothi Rangineni, PhD - Senior Process Scientist, Fluid Air
- Yogesh Sanghvi, PhD - President, Rasayan Inc.
Multidrug-resistant Gram-negative bacteria pose an increasing threat to human health, and development of novel antibiotics would be one answer to this challenge. Most efforts to date have focused on development of broad- spectrum antibiotics and unfortunately with limited success in terms of approved new drugs. As an alternative approach we have developed an RNA therapeutics platform based on peptide nucleic acid (PNA) antisense technology that allows rational discovery and development of designer precision, narrow spectrum antibiotics optimized to target different multidrug resistant bacterial species using the same platform and principle. Using this platform, PNA antisense antibiotics (PAAs) showing (sub)micromolar antibacterial activity against Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa (including multidrug resistant clinical isolates) have been discovered. Lead compounds are bactericidal via an antisense mechanism of action, exhibit low frequency of resistance, have exquisite biostability in human (and mouse ) serum, very low toxicity in human cell culture (HepG2), good in vivo tolerability in mice via sc, iv and ip administration. Finally, in vivo efficacy against MDR E. coli and A, baumannii in urinary tract infection, sepsis and soft tissue infection mouse models has been demonstrated. Based on these in vitro as well as in vivo results the prospects of developing novel precision antisense antibiotics against infections by multidrug resistant Gram-negative bacteria will be discussed.
- Peter Nielsen, PhD - Professor, University of Copenhagen
RNA aptamers have established themselves in ophthalmology with two approved products for intravitreal injection, but not yet for systemic administration. Recent clinical progress of olaptesed pegol (NOX-A12), an L-stereoisomer RNA aptamer, in the treatment of one of the most aggressive brain tumors, glioblastoma will highlight the potential of this class in systemic therapies.
- Aram Mangasarian, Ph.D. - Chief Executive Officer, TME Pharma
Secarna Pharmaceuticals is an antisense oligonucleotide (ASO) discovery company with a diversified pre-clinical pipeline based on LNA-modified ASOs. We will present data showing promising anti-tumor activity of ASOs targeting Neuropilin 1 (NRP1) in mouse tumor models with a detailed analysis of the mechanism of action. Furthermore, we will demonstrate that ASOs are a modality that is suited well for treatment of kidney diseases such as acute kidney injury and we will disclose Secarna’s lead project in this indication.
- Frank Jaschinski, PhD. - Chief Scientific Officer, Secarna Pharmaceuticals
- Sonja Merkas, Ph.D. - Founder, Livinovea
The presentation will showcase Biogen’s efforts to scale LPOS to 2.5kg and then to 25 kg in readiness to GMP manufacturing. Highlight the synthetic and analytical challenges and then look ahead to new technologies developed in-house that could help to simplify the manufacturing process.
- Yannick Fillon, PhD - Head of Oligonucleotide Process Chemistry, Biogen
An overview of current methodologies and opportunities to apply biocatalysis to address challenges in oligonucleotides manufacturing will be provided. Pros and cons of the different biocatalytic strategies reported to date will be analyzed, with a special emphasis on the CMC perspective. Finally, a case-study will be discussed, showing how biocatalysis can enable oligonucleotide manufacturing and improve quality attributes.
- Filippo Sladojevich, Ph.D. - Senior Principal Scientist, Hoffmann-La Roche
Isolating oligonucleotides as aqueous solutions can enhance safety, sustainability, and efficiency of drug manufacturing process. The design of the drug substance manufacturing facility should incorporate principles from both small molecule and biologics manufacturing. A careful selection of drug substance matrix can facilitate forward processing to drug product and lower exposure risk compared to powder. Recognizing solution oligonucleotides as drug substance can streamline manufacturing process and improve efficiency.
- Ashish Garg, Ph.D. - Director, Drug Product Development, Eli Lilly and Company
- Christian Becker, Ph.D. - Professor and Head of the Institute of Biological, University of Vienna
Disulfide-constrained peptides have gained interested due to their intrinsic stable properties and the plasticity of the loops protruding from the core of the peptide. Capitalizing on these intrinsic properties we are building a powerful display platform to produce peptide leads for clinically validated targets.
- Christina Schroeder, Ph.D. - Senior Fellow, Peptide Therapeutics, Genentech
My laboratory is involved in the discovery and development of cyclic peptides for therapeutic applications. In recent years, we have begun to address the long-standing goal of developing target-specific peptides that are membrane-permeable and orally available. To this end, we are focusing on the generation of cyclic peptides that have a relatively small size (< 800 Da) and a limited polar surface area, so that they have a high chance of passively crossing membranes. To generate sub-kilodalton cyclic peptides that bind to disease targets of interest, we have established an approach based on nanomole-scale cyclic peptide synthesis and high-throughput screening of crude products (1, 2). In short, we generate thousands of peptides by solid-phase peptide synthesis and combinatorially diversify them by reacting them with a myriad of chemical building blocks. In this approach, all reagents are transferred in nanolitre volumes by acoustic dispensing and reactions are performed at the nanomole scale, allowing tens of thousands of cyclic peptides to be synthesised and screened in a short time. Recently, we have shown that cyclic peptides developed using this approach can achieve good oral availability (3). In my talk, I will explain the approach to the synthesis and screening of cyclic peptide libraries, show examples of libraries and their screening, present nanomolar ligands we have developed against different proteins, including a protein-protein interaction target, and show data on the membrane permeability and oral availability of the peptides. [1] S. Kale, et al., Science Advances. 2019, 5 (8). [2] S. Habeshian, et al., Nature Communications. 2022, 13 (3823) [3] M.L. Merz, et al., Nature Chemical Biology. 2023.
- Christian Heinis, PhD - Associate Professor, Ecole PolyTechnique Federale de Lausanne
Membrane receptor proteins are essential in cellular signaling. In recent years, there has been a surge of interest in discovering peptide binders to membrane receptors due to their potential use for diagnostic, therapeutic, and theranostic purposes. Phage display technology is frequently employed to identify peptide binders to recombinant proteins. Improper folding of recombinant proteins, a well-known challenge, would hinder the identification of peptide binders. In our lab, we developed a cell-based model to overexpress membrane proteins for phage display biopanning to ensure reliable identification of cyclic peptide binders. In this presentation, we show different examples of novel CLIPSTM peptides with excellent binding affinities and selectivities to the protein of interest that were identified using our novel cell-based model. We illustrate the techniques that enable cell-based biopannings using a benchmark membrane protein. Additionally, we will share preliminary data on a “real” difficult-to-target protein for which a recombinant alternative is currently unavailable. The work presented convincingly illustrates that cell-based biopanning is a reliable model for discovering peptide binders to membrane-bound proteins that are difficult to target using the recombinant form of that same protein.
- Sheena Ong, PhD - Scientist, Biosynth
- Rocky Liu - International Business Director, Wuhu Huaren
- Meri Cizmar - Teamlead GMP Production, LGC Axolabs Berlin GmbH
Recently, RNA therapies emerged as a new treatment modality for heart failure. Here I will give an overview from basic mechanistic insights, preclinical development and first experiences in clinical trials.
- Janika Viereck, PhD - Head of R&D, Cardior Pharmaceuticals GmbH - a Novo Nordisk company
- Erich Koller, Ph.D. - Senior Principal Scientist, Roche Innovation Center Basel
In this presentation, we will show the proof-of-concept, pre-clinical safety data and results from Phase I clinical trial in healthy volunteers treated with our drug candidate named IMT504. IMT504 is a noncoding, non-CpG, single strand oligonucleotide (ODN) with immune-modulating and opioid-sparing properties. Then, we will move to Phase II/III clinical trial in patients suffering from Complex Regional Pain Syndrome (CRPS). CRPS is an orphan drug disease that usually affects an arm or a leg; and it is typically developed after an injury, a surgery or a stroke. The pain in this patients is out of proportion to the severity of the initial injury. The sponsor of the clinical trial is Immunalgia Therapeutics, a biotech company incubated at the National Scientific and Technical Research Council in Argentina.
- Alejandro Montaner - CEO, Immunalgia Therapeutics
The currently largest European manufacturing plant for Oligonucleotides has been built in Switzerland in 2020-2022. Since the first batch started in August 2022 several drug substance batches have been successfully produced. The main challenges encountered during the design phase, including low bioburden related activities, consumables selection, management of water and solvents are discussed. In addition selected cases encountered during manufacturing of Leqvio drug substance are presented.
- Letizia Volpe, Ph.D. - Site MS&T Head Chemical Operations, Novartis
Oligonucleotides are dream molecules for an NMR spectroscopist. So many aspects related to both structure and content can be studied by NMR. Total content determination is performed by the internal standard 31P platform qNMR method for both drug substance and drug product. Correct hydrogen bonding in the loop in one RNA strand, is furthermore confirmed by using a 2D 1H-15N platform method at natural abundance.
- Joan Malmstrøm, Ph.D. - Principal Scientist, CMC Analytical Support, Novo Nordisk A/S
- Sonja Merkas, Ph.D. - Founder, Livinovea
- Yannick Fillon, PhD - Head of Oligonucleotide Process Chemistry, Biogen
- Filippo Sladojevich, Ph.D. - Senior Principal Scientist, Hoffmann-La Roche
- Ashish Garg, Ph.D. - Director, Drug Product Development, Eli Lilly and Company
- Letizia Volpe, Ph.D. - Site MS&T Head Chemical Operations, Novartis
Herantis Pharma has developed a novel D-amino acid peptide HER-096 that mimicks the active site of the neuroprotective and neurorestorative CDNF protein, and efficiently penetrates the blood-brain barrier allowing peripheral administration. Subcutaneously administered HER-096 has shown great efficacy in a preclinical Parkinson’s disease animal model. A phase 1a clinical study demonstrated good safety & tolerability profile and efficient blood-brain barrier penetration in healthy volunteers.
- Antti Vuolanto - Chief Executive Officer, Herantis Pharma plc
Using the streaMLine platform, we have developed GUBamy a long-acting amylin analogue with attractive therapeutic applications. GUBamy is an amylin receptor selective analogue with improved physical and chemical properties allowing formulation at neutral pH. GUBamy shows 10 % weight loss in DIO rats, and its pre-clinical PK makes it suitable for once weekly dosing in humans. GUBamy is currently in phase I.
- Morten Lundh, Ph.D. - Director, Drug Discovery Innovation, Gubra A/S
- Christian Becker, Ph.D. - Professor and Head of the Institute of Biological, University of Vienna
This presentation will explore the oligo manufacturing process – from synthesis through concentration – and the applicable equipment considerations for effective technical implementation. It will also introduce the latest innovations from Asahi Kasei Bioprocess that allow for a nearly complete manufacturing line offering.
- Tom Krebstakies, PhD - Sales Manager - Europe & Asia, Asahi Kasei Bioprocess
- Charlotte LeKieffre, PhD - Biopharma Application Specialist, Agilent Technologies
- Ralph Beneke - Market specialist molecular biology research, Agilent Technologies
- Amanda Haas - Business Development Manager, Gene Editing Therapeutics, Agilent Technologies
- Daniel Bachmann, PhD - Business Development Manager, Bachem AG
- Kangming Chen, PhD - Head of mRNA & Plasmid Department, GenScript
- Jiazhen Liang, PhD - Senior Scientist, GenScript
In this presentation learn how LCMS together with new software solutions is used to easily identify impurities, improve the characterization of oligonucleotides and by the application of a new fragmentation technique is increasing the sequence coverage of oligonucleotides. As targets move to larger oligonucleotides and the thousands of bases of mRNA capillary electrophoresis (CE) is helping to profile impurities. In this presentation we will discuss how chemical kits together with CE are enabling scientists to detect size impurities from gRNA and the prime editing guide RNA used for CRIPSR to the mRNA found in lipid nanoparticles. Finally discover how CE is applied to measuring genome titre and together with viral protein detection can be used to calculate the empty / full ration of viral particles used in cell and gene therapy products.
- Stephen Lock, PhD - Senior Market Development Manager, SCIEX
Improving understanding of processes offers dual benefits for oligonucleotide development. Firstly, it establishes a potential platform for creating similar molecules with different sequences, thereby accelerating process development time /efforts. Secondly, it ensures robust processes that yield high-quality APIs. While Quality by Design (QbD) is often equated with Design of Experiments (DoE), it actually encompasses overall process design, with DoE being just one aspect. We'll explore how embracing QbD principles can optimize process understanding and utilization of data, including examples of how mathematical modeling systematically gathers data, enhances process understanding , and contributes to process characterization in solid-supported synthesis.
While alternative methods are being explored, solid-supported synthesis remains the most established and practical approach for producing oligonucleotides, especially in smaller quantities. Before 2016, the main focus was on introducing oligonucleotides as therapeutics. However, with over 15 approvals in an 8-year period, and considering the potential for a platform approach, developing a strategy for process characterization would greatly benefit the overall oligonucleotide portfolio and streamline the filing process with a deeper understanding. This study emphasizes the importance of the Quality by Design (QbD) concept from development through to product lifecycle. Using case studies to model specific unit operations like TFF, we demonstrate how this approach can provide regulatory benefits.
Recent RNA approvals highlight the need for robust analytical methods to monitor critical quality attributes (CQAs), ensuring control of manufacturing processes and product quality. Oligonucleotide mapping via liquid chromatography / mass spectrometry is effective for CQA assessment, however, sample preparation approaches and data handling present a time-consuming challenge. A novel digestion procedure, data acquisition and data processing workflow was developed to produce fragment assignments for sgRNA and mRNA, including measurement of key CQAs
- Jonathan Fox - Consulting Scientist, Waters Corporation
- Troels Koch, PhD - Chief Technology Officer, MiNa Therapeutics
RNA editing technologies have the potential to become a new class of innovative medicines with applicability to a broad range of therapeutic areas. Two technologies (Axiomer and Trident) currently in development use editing oligonucleotides to mediate single nucleotide changes at the RNA level in a highly specific and targeted way using endogenous molecular machinery. Axiomer uses Adenosine Deaminase acting on RNA, or ADAR, and Trident uses pseudouridine synthase, which are naturally present in human cells. This presentation will report insights into structure-activity relationship (SAR) and delivery optimization for these technologies. Additionally, pioneering activities to unfold new opportunities in the field, including the development of reliable in vitro and in vivo models (including non-human primates), and efforts to maximize translatability for the development of new medicines addressing unmet medical needs will be presented.
- Bart Klein - Senior VP of Axiomer Technology, ProQR Therapeutics
- Erich Koller, Ph.D. - Senior Principal Scientist, Roche Innovation Center Basel
- Beatriz Llamusi, PhD - Chief Executive Officer & Co Founder, Arthex Biotech S.L.
- Daniel Waschke, Ph.D. - Technical Regulatory Manager, F. Hoffmann-La Roche Ltd.
- René Thürmer, PhD - Deputy Head, BfArM Federal Institute for Drugs & Medical Devices
QurAlis is developing precision therapies, targeting genetic drivers in sub-forms of ALS. Two of QurAlis’ programs are in early phase clinical trials. One of these programs is a splice modulator ASO delivered by intrathecal injection. The talk will focus on how to successfully prepare for IND/IMPD regulatory submissions with regulatory expectations changing over time.
- Hagen Cramer, PhD - Chief Technology Officer, QurAlis
- Tracey Burr, Ph.D. - Executive Director, CMC Regulatory Affairs, Ionis Pharmaceuticals
- Riccardo Bernasconi, Ph.D. - Director Business Development, Bachem
In recent years there has been increased interest in using peptides as therapeutics, especially since the introduction of peptide drug substances Semaglutide and Tirezepetide into the market. This talk will describe strategies we use at AstraZenca to develop close to commercial processes to deliver peptide drug substance, where the key performance indicators are cost of goods, throughput and sustainability.
- Gajan Santhakumar, Ph.D. - Associate Principal Scientist, Early Chemical Development, AstraZeneca
Advancements in real-time process analytical technologies (PAT) have significantly improved insights into chromatographic processes. However, the complexity of model building, associated equipment and mathematical algorithms often requires extensive development and restricts applications to late-stage processes.
We present a streamlined PAT approach based on selected wavelengths in the UV/Vis range, tailored to early-stage development of purification processes for peptides, and for transfer to multi-purpose production facilities. The approach presented ensures fast development cycles and increases flexibility in large-scale production.
- Jörg Kittelmann, Ph.D. - Principal Scientist, CMC Downstream API Development, Novo Nordisk
- Sophie Corbet - EMEA Bioprocessing Technical Service Manager, DuPont
- Mathew Miller, PhD - Director, Life Science and RNA Technologies, Codexis
AIC468 is a direct-acting antiviral antisense oligonucleotide (ASO) which inhibits the correct splicing of the mRNA coding for the BKV master regulator large T-antigen. Targeting all BKV genotypes and subtypes, this chemically modified ASO naturally homes to the kidney where it inhibits viral replication. In vivo proof of principle was shown in a transgenic mouse model. A good pharmacokinetic profile with highest exposure in the target organ kidney and favorable nonclinical safety data support the start of a combined single/multiple dose phase 1 trial.
- Eric van der Veer, PhD - Chief Innovation Officer, Hybridize Therapeutics
- Tamara Pfaff - Head of Preclinical Development, AiCuris Anti-infective Cures AG
This presentation covers the pivotal role of advancements in chemical design variants and delivery systems in enhancing the state of the art of siRNA. It highlights these improvements' impact on siRNA's stability, specificity and efficacy, and explores how these breakthroughs could make siRNA a game-changer in the treatment of various diseases.
- Tomaz Einfalt, PhD - Principal Investigator II xRNA, Novartis Institutes for BioMedical Research
Novartis' first marketed siRNA oligonucleotide, inclisiran, is approved in 90+ countries around the globe, including EU and US, for the treatment of hypercholesterolemia. In this presentation, we will share our post-approval experiences with Health Authorities, discuss the key CMC aspects that require careful consideration and planning and highlight the learnings and best practices that can facilitate a successful and efficient regulatory CMC post-approval process for siRNA oligonucleotides.
- Daniela Fischer, Ph.D. - Associate Director Regulatory Affairs CMC, Novartis Pharmaceutical Manufacturing
- Sergey Tsukanov, Ph.D. - Senior Director Chemistry, Eli Lilly and Company
- Alexander Kleinsmann, PhD - Director R&D, CMC Development, Bachem AG
- Yi Yang, PhD - Lead Scientist, Ferring Pharmaceuticals A/S